| dexlansoprazole / Generic mfg. |
NCT01642602 / 2012-001680-72: Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents |
|
|
| Completed | 2 | 104 | US, Europe, RoW | Dexlansoprazole, Dexilant, TAK-390MR | Takeda | Gastroesophageal Reflux Disease | 01/14 | 01/14 | | |
NCT01642615 / 2012-001681-15: Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents |
|
|
| Completed | 2 | 63 | US, Europe, RoW | Dexlansoprazole, Dexilant, Placebo | Takeda | Gastroesophageal Reflux Disease, Erosive Esophagitis | 11/14 | 11/14 | | |
NCT02162758: Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation |
|
|
| Terminated | 2 | 6 | US | Dexlansoprazole, Dexilant, Dexlansoprazole Placebo | Takeda | Barrett's Esophagus | 04/16 | 04/16 | | |
NCT01479231: Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis |
|
|
| Withdrawn | 1/2 | 0 | US | dexlansoprazole, Dexilant | Mayo Clinic | Gastroesophageal Reflux Disease, Eosinophilic Esophagitis, Dysphagia | 03/12 | 03/12 | | |
